KR102108377B1 - α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH - Google Patents

α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH Download PDF

Info

Publication number
KR102108377B1
KR102108377B1 KR1020197022294A KR20197022294A KR102108377B1 KR 102108377 B1 KR102108377 B1 KR 102108377B1 KR 1020197022294 A KR1020197022294 A KR 1020197022294A KR 20197022294 A KR20197022294 A KR 20197022294A KR 102108377 B1 KR102108377 B1 KR 102108377B1
Authority
KR
South Korea
Prior art keywords
fsh
rfsh
leu
lys
sialylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197022294A
Other languages
English (en)
Korean (ko)
Other versions
KR20190092608A (ko
Inventor
이안 코팅햄
다니엘 플락신
리차드 보이드 화이트
Original Assignee
페링 인터내셔널 센터 에스 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102108377(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 페링 인터내셔널 센터 에스 에이 filed Critical 페링 인터내셔널 센터 에스 에이
Publication of KR20190092608A publication Critical patent/KR20190092608A/ko
Application granted granted Critical
Publication of KR102108377B1 publication Critical patent/KR102108377B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197022294A 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH Expired - Fee Related KR102108377B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187023820A Division KR20180095140A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Publications (2)

Publication Number Publication Date
KR20190092608A KR20190092608A (ko) 2019-08-07
KR102108377B1 true KR102108377B1 (ko) 2020-05-08

Family

ID=39717519

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197022294A Expired - Fee Related KR102108377B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020167012148A Ceased KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020107025581A Active KR101622944B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020187023820A Ceased KR20180095140A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020177026920A Ceased KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020167012148A Ceased KR20160056960A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020107025581A Active KR101622944B1 (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020187023820A Ceased KR20180095140A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH
KR1020177026920A Ceased KR20170110741A (ko) 2008-04-16 2009-04-16 α2,3- 및 α2,6-시알화를 포함하는 재조합 FSH

Country Status (29)

Country Link
US (7) US8951967B2 (cg-RX-API-DMAC7.html)
EP (7) EP3098234B1 (cg-RX-API-DMAC7.html)
JP (7) JP2011519359A (cg-RX-API-DMAC7.html)
KR (5) KR102108377B1 (cg-RX-API-DMAC7.html)
CN (3) CN105906703A (cg-RX-API-DMAC7.html)
AR (1) AR071479A1 (cg-RX-API-DMAC7.html)
AU (5) AU2009237479B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910461B8 (cg-RX-API-DMAC7.html)
CA (1) CA2725257A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115413T1 (cg-RX-API-DMAC7.html)
DK (6) DK3098234T3 (cg-RX-API-DMAC7.html)
ES (5) ES2989729T3 (cg-RX-API-DMAC7.html)
FI (4) FI4015527T3 (cg-RX-API-DMAC7.html)
FR (3) FR17C1020I2 (cg-RX-API-DMAC7.html)
HR (5) HRP20241187T1 (cg-RX-API-DMAC7.html)
HU (9) HUE033830T2 (cg-RX-API-DMAC7.html)
IL (2) IL208538A (cg-RX-API-DMAC7.html)
LT (8) LT3045471T (cg-RX-API-DMAC7.html)
MX (3) MX348622B (cg-RX-API-DMAC7.html)
NO (4) NO2017025I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588381A (cg-RX-API-DMAC7.html)
PL (6) PL2808340T3 (cg-RX-API-DMAC7.html)
PT (6) PT3144318T (cg-RX-API-DMAC7.html)
RU (3) RU2682270C2 (cg-RX-API-DMAC7.html)
SA (1) SA109300228B1 (cg-RX-API-DMAC7.html)
SI (6) SI2808340T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488640B (cg-RX-API-DMAC7.html)
WO (1) WO2009127826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007373B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
CN118922201A (zh) 2022-04-01 2024-11-08 辉凌公司 治疗不育症的混合方案
KR20250016113A (ko) 2022-05-26 2025-02-03 훼링 비.브이. 남성 불임 치료를 위한 조성물 및 방법
MA71382A (fr) 2022-07-08 2025-04-30 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)
KR20260041113A (ko) 2023-07-20 2026-03-26 훼링 비.브이. 서방형의 약물-로딩된 마이크로입자

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035686A2 (en) * 2001-10-22 2003-05-01 Applied Research Systems Ars Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
US20060234352A1 (en) 2000-12-05 2006-10-19 Applied Research Systems Ars Holding N.V. Homogeneity and secretion of recombinant proteins in mammalian systems

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
CA2372714A1 (en) 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234352A1 (en) 2000-12-05 2006-10-19 Applied Research Systems Ars Holding N.V. Homogeneity and secretion of recombinant proteins in mammalian systems
WO2003035686A2 (en) * 2001-10-22 2003-05-01 Applied Research Systems Ars Holding N.V. Compositions of fsh with high sialylation degree and their use for the preparation of medicaments

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Appl. Microbiol. Biotechnol. Vol.68:283-291 (2005)*
Human Reproduction Vol.15(9):1898-1902 (2000)
Journal of Clinical Endocrinology and Metabolism Vol.79(3):756-759 (1994)
Molecular Human Reproduction Vol.2(5):371-382 (1996)

Also Published As

Publication number Publication date
EP2268666A1 (en) 2011-01-05
SI3045471T1 (sl) 2017-07-31
KR20110005863A (ko) 2011-01-19
LT2808340T (lt) 2016-11-10
HRP20170958T1 (hr) 2017-09-22
PL3098234T3 (pl) 2025-01-07
JP2011519359A (ja) 2011-07-07
HUS2500029I1 (hu) 2025-07-28
FI3098234T3 (fi) 2024-10-31
EP3045471B1 (en) 2017-03-29
LT3098234T (lt) 2024-09-10
RU2745557C1 (ru) 2021-03-29
US20110105398A1 (en) 2011-05-05
JP6762916B2 (ja) 2020-09-30
CA2725257A1 (en) 2009-10-22
DK4015527T3 (da) 2025-04-14
SI3144318T1 (sl) 2020-12-31
ES2629392T3 (es) 2017-08-09
SI4015527T1 (sl) 2025-05-30
AU2017204258A1 (en) 2017-07-20
US9546204B2 (en) 2017-01-17
FR25C1025I1 (fr) 2025-09-19
EP3098234B1 (en) 2024-07-31
NO2025006I1 (no) 2025-01-16
HUE068565T2 (hu) 2025-01-28
US11952407B2 (en) 2024-04-09
AU2014203277C1 (en) 2017-07-27
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
CY1115413T1 (el) 2017-01-04
NO2017025I1 (no) 2017-06-06
JP2017060476A (ja) 2017-03-30
HUS1700025I1 (hu) 2017-06-28
AU2014203277B2 (en) 2017-04-06
WO2009127826A1 (en) 2009-10-22
PT4015527T (pt) 2025-04-10
NO2025032I1 (no) 2025-07-14
EP3144318A1 (en) 2017-03-22
RU2745557C3 (ru) 2021-12-10
SI2808340T1 (sl) 2016-12-30
SI2268666T1 (sl) 2014-07-31
PT2808340T (pt) 2016-11-21
RU2537268C2 (ru) 2014-12-27
BRPI0910461A8 (pt) 2018-10-16
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
EP3045471A1 (en) 2016-07-20
LT3045471T (lt) 2017-07-10
US20150065695A1 (en) 2015-03-05
CN105906703A (zh) 2016-08-31
ES3023526T3 (en) 2025-06-02
PL2268666T3 (pl) 2014-08-29
FR17C1020I1 (cg-RX-API-DMAC7.html) 2020-04-10
HUE033830T2 (en) 2018-01-29
US20180079794A1 (en) 2018-03-22
HUE030652T2 (en) 2017-05-29
DK3098234T3 (da) 2024-10-21
JP6486310B2 (ja) 2019-03-20
US20240327487A1 (en) 2024-10-03
PT3045471T (pt) 2017-06-14
BRPI0910461A2 (pt) 2018-03-27
HUS2500008I1 (hu) 2025-02-28
KR20180095140A (ko) 2018-08-24
PT3144318T (pt) 2020-11-04
US9771407B2 (en) 2017-09-26
AU2017225020A1 (en) 2017-09-28
EP4015527B1 (en) 2025-01-22
FIC20250025I1 (fi) 2025-07-11
EP3098234A1 (en) 2016-11-30
JP7316905B2 (ja) 2023-07-28
AU2017225020B2 (en) 2019-11-14
LTPA2017018I1 (lt) 2017-06-26
ZA201007373B (en) 2011-06-29
FR17C1020I2 (fr) 2020-04-10
FIC20250003I1 (fi) 2025-01-15
US20210332099A1 (en) 2021-10-28
US10995128B2 (en) 2021-05-04
RU2014141994A (ru) 2016-05-10
JP2024038000A (ja) 2024-03-19
SI3098234T1 (sl) 2024-10-30
US8951967B2 (en) 2015-02-10
PT3098234T (pt) 2024-10-21
TW200948378A (en) 2009-12-01
RU2010141908A (ru) 2012-05-27
IL208538A (en) 2014-03-31
KR20160056960A (ko) 2016-05-20
AR071479A1 (es) 2010-06-23
HRP20241187T1 (hr) 2024-12-06
MX348622B (es) 2017-06-22
HUS1700036I1 (hu) 2017-10-30
JP2015120696A (ja) 2015-07-02
DK2268666T3 (da) 2014-05-12
TWI488640B (zh) 2015-06-21
BRPI0910461B8 (pt) 2021-05-25
CN102066414A (zh) 2011-05-18
US12516094B2 (en) 2026-01-06
FR25C1003I1 (fr) 2025-02-28
RU2014141994A3 (cg-RX-API-DMAC7.html) 2018-05-28
ES2468318T3 (es) 2014-06-16
AU2009237479A1 (en) 2009-10-22
US20160347811A1 (en) 2016-12-01
AU2017204259B2 (en) 2017-08-17
IL230571A (en) 2015-11-30
BRPI0910461B1 (pt) 2021-02-23
JP2020040956A (ja) 2020-03-19
HUE071059T2 (hu) 2025-07-28
KR20190092608A (ko) 2019-08-07
ES2989729T3 (es) 2024-11-27
DK2808340T3 (en) 2016-12-05
AU2017204259A1 (en) 2017-07-20
NO2017050I1 (no) 2017-09-28
LT4015527T (lt) 2025-04-10
EP2808340A1 (en) 2014-12-03
IL208538A0 (en) 2010-12-30
PL2808340T3 (pl) 2017-02-28
PL3144318T3 (pl) 2021-02-08
HRP20161520T1 (hr) 2016-12-30
RU2682270C2 (ru) 2019-03-18
HUE030652T4 (en) 2017-09-28
HRP20250313T1 (hr) 2025-05-09
HK1146284A1 (en) 2011-05-20
LTPA2017029I1 (lt) 2017-10-10
EP2268666B1 (en) 2014-03-12
LTPA2025505I1 (cg-RX-API-DMAC7.html) 2025-02-10
AU2017204258B2 (en) 2017-08-17
HK1199039A1 (en) 2015-06-19
KR20170110741A (ko) 2017-10-11
JP2018021037A (ja) 2018-02-08
DK3144318T3 (da) 2020-12-07
JP2022031652A (ja) 2022-02-22
US20260217782A1 (en) 2026-07-30
AU2009237479B2 (en) 2014-05-15
CN105906702A (zh) 2016-08-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
AU2014203277A1 (en) 2014-07-24
SA109300228B1 (ar) 2014-04-08
EP3144318B1 (en) 2020-09-23
NZ588381A (en) 2012-05-25
MX355457B (es) 2018-04-19
PT2268666E (pt) 2014-06-25
HUS1700024I1 (hu) 2017-06-28
DK3045471T3 (en) 2017-06-26
EP2808340B1 (en) 2016-08-17
FI4015527T3 (fi) 2025-04-29
LTPA2025525I1 (cg-RX-API-DMAC7.html) 2025-07-25
EP4015527A1 (en) 2022-06-22
EP2722339A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
JP7316905B2 (ja) アルファ2,3-およびアルファ2,6-シアリル化を含む組換えfsh
HK40068781B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1233276B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227049B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1199039B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1227046B (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
HK1197825A (en) Recombinant fsh including alpha 2,3-and alpha 2,6-sialylation

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250430

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250430

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250430